On January 6, 2023, Beijing Scitop Bio-tech Co., Ltd. closed the transaction. The company issued 26,737,967 shares at an issue price of CNY 26.18 per share for gross proceeds of CNY 699,999,976.06. The transaction included participation from Sun Tiansong for 1,336,899 shares for CNY 35,000,015.82 for 26.33% stake; Caitong Fund Management Co., Ltd., for 6,608,097 shares for CNY 172,999,979.46; Nuode Asset Management Co., Ltd. for 6,417,112 shares for CNY 167,999,992.16; China Southern Asset Management Co., Ltd. for 2,750,190 shares for CNY 71,999,974.20; JIC Investment Co., Ltd. for 2,291,825 shares for CNY 59,999,978.50; Shenwan Hongyuan Securities Co., Ltd., Investment Arm for 1,909,854 shares for CNY 49,999,977.72; Hunan Shenghua Lihe Information Industry Venture Capital Fund Partnership Enterprise (L.P.), a fund managed by Shanghai Grand Force Investment Management Co.

Ltd. for 1,909,854 shares for CNY 49,999,977.72; Huatai Asset Value Selected Asset Management Products for 1,336,898 shares for CNY 34,999,989.64; Huatai Youyi No. 5 Hybrid Pension Product-Bank of China Limited for 1,336,898 shares for CNY 34,999,989.64; and Huatai Asset Value Preferred Asset Management Product for 840,340 shares for CNY 22,000,101.20. All securities issued in the transaction have hold period of 6 months.

The company incurred total issuance expenses of CNY 14,097,643.28 and raised net proceeds of CNY 685,902,332.78 in the transaction.